Monday, April 27, 2026 9:09:24 PM
Hey bro (or sis) I’m making an exception and replying to you politely, as I admit you’ve been right and I’ve been wrong for many months.
Also, although IMHO it’s far from “clear”, you make a good point about conditional approval. This is my main concern with the MAA, As there have been several indicators that nice will not be reimbursing anytime soon.
For example, there is the addition of DC VAX to the high cost alternative funding NHS drug list, LPs repeated comments about proceeding with commercialization/launch regardless of nice reimbursement, the simple fact that most other companies would have filed evidence with nice a long time ago and it appears that NWBO is still waiting on something, GZ’s acknowledging that conditional approval is possible (I thought for sure they’d know by now) and of course, the fact that approval is just taking so long, which Baxers has outlined is more common in treatments with conditional approval.
While am bullish at these levels, I am not blind or unwilling to hear, rational parish arguments, so I will not be surprised if there is some form of conditional approval. Because of the safety profile, I still think they get full approval, but I realize that It is possible that the use of ECA’s make it more likely that efficacy could be called into question and they could require some form of confirmatory trials.
Also, although IMHO it’s far from “clear”, you make a good point about conditional approval. This is my main concern with the MAA, As there have been several indicators that nice will not be reimbursing anytime soon.
For example, there is the addition of DC VAX to the high cost alternative funding NHS drug list, LPs repeated comments about proceeding with commercialization/launch regardless of nice reimbursement, the simple fact that most other companies would have filed evidence with nice a long time ago and it appears that NWBO is still waiting on something, GZ’s acknowledging that conditional approval is possible (I thought for sure they’d know by now) and of course, the fact that approval is just taking so long, which Baxers has outlined is more common in treatments with conditional approval.
While am bullish at these levels, I am not blind or unwilling to hear, rational parish arguments, so I will not be surprised if there is some form of conditional approval. Because of the safety profile, I still think they get full approval, but I realize that It is possible that the use of ECA’s make it more likely that efficacy could be called into question and they could require some form of confirmatory trials.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
